Related Experiment Video
Updated: Sep 4, 2025
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls
Hua-Jay J Cherng1, Jason R Westin2
1Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Tafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. This combination was superior to routine immunochemotherapy regimens when comparing matched observational cohorts. "Synthetic" control groups may support use of novel DLBCL therapies in the absence of randomized studies. See related article by Nowakowski et al., p. 4003.
More Related Videos
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017